Chemotherapy-induced Nausea and Vomiting: Optimizing Prevention and Management

Overview

Journal Am Health Drug Benefits

Date 2014 Jul 4

PMID 24991322

Citations 28

Authors

Kamakshi V Rao

Aimee Faso

Affiliations

Soon will be listed here.

Abstract

Background: Nausea and vomiting are serious side effects of cancer chemotherapy that can cause significant negative impacts on patients' quality of life and on their ability to tolerate and comply with therapy. Despite advances in the prevention and management of chemotherapy-induced nausea and vomiting (CINV), these side effects remain among the most distressing for patients.

Objective: To discuss CINV and the current pharmacologic approaches to its management.

Discussion: This article outlines the mechanism of CINV followed by a review of current approaches to pharmacologic therapy and current practice guidelines from national cancer organizations. This information will help providers and payers understand the optimal management of patients with CINV including practical considerations and value-based decision-making that considers cost issues.

Conclusion: Numerous preventive and treatment options are available to manage CINV Addressing antiemetic regimens requires ongoing patient evaluation to determine the best approach for each individual patient.

Citing Articles

Prescription patterns of supportive care medications among children receiving chemotherapy treatments at a major referral hospital in Tanzania: where are we in managing chemotherapy-induced toxicities?.

Katabalo D, Abraham M, Kidenya B, Liwa A, Schroeder K Front Oncol. 2025; 15:1444565.

PMID: 40071090 PMC: 11893393. DOI: 10.3389/fonc.2025.1444565.

Comparison of efficacy and safety between palonosetron and ondansetron to prevent postoperative nausea and vomiting in patients undergoing non-laparoscopic surgery: A systematic review and meta-analysis of randomised controlled trials.

Lal B, Alagarsamy R, Kumar J, Rai A, Yadav V, Joshi R Indian J Anaesth. 2025; 69(1):108-122.

PMID: 40046699 PMC: 11878355. DOI: 10.4103/ija.ija_1017_24.

Neuroprotective Effects of Trimetazidine against Cisplatin-Induced Peripheral Neuropathy: Involvement of AMPK-Mediated PI3K/mTOR, Nrf2, and NF-B Signaling Axes.

Elbaset M, Afifi S, Esatbeyoglu T, Abdelrahman S, Saleh D Oxid Med Cell Longev. 2024; 2024:6612009.

PMID: 39502494 PMC: 11535264. DOI: 10.1155/2024/6612009.

Acupressure On Chemotherapy-Induced Nausea and Vomiting among Breast Cancer Patients: A Systematic Review and Meta-analysis.

Issac A, Nayak S, Halemani K, Mishra P, Chand G Asian Pac J Cancer Prev. 2024; 25(10):3421-3428.

PMID: 39471007 PMC: 11711357. DOI: 10.31557/APJCP.2024.25.10.3421.

The Therapeutic Mechanisms of Honey in Mitigating Toxicity from Anticancer Chemotherapy Toxicity: A Review.

Bose D, Famurewa A, Akash A, Othman E J Xenobiot. 2024; 14(3):1109-1129.

PMID: 39189178 PMC: 11348124. DOI: 10.3390/jox14030063.

References

Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice J . Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol. 2011; 29(11):1495-501. DOI: 10.1200/JCO.2010.31.7859. View

Herman T, Einhorn L, Jones S, Nagy C, Chester A, Dean J . Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med. 1979; 300(23):1295-7. DOI: 10.1056/NEJM197906073002302. View

Hesketh P, Grunberg S, Gralla R, Warr D, Roila F, de Wit R . The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052.... J Clin Oncol. 2003; 21(22):4112-9. DOI: 10.1200/JCO.2003.01.095. View

Mantovani G, Maccio A, Esu S, Lai P . Evidence that cisplatin induces serotonin release from human peripheral blood mononuclear cells and that methylprednisolone inhibits this effect. Eur J Cancer. 1996; 32A(11):1983-5. DOI: 10.1016/0959-8049(96)00204-3. View

Morrow G . Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol. 1984; 2(10):1170-6. DOI: 10.1200/JCO.1984.2.10.1170. View

Rojas C, Stathis M, Thomas A, Massuda E, Massuda E, Alt J . Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg. 2008; 107(2):469-78. DOI: 10.1213/ane.0b013e318172fa74. View

Ioannidis J, Hesketh P, Lau J . Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol. 2000; 18(19):3409-22. DOI: 10.1200/JCO.2000.18.19.3409. View

Steele N, Gralla R, Braun Jr D, Young C . Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treat Rep. 1980; 64(2-3):219-24. View

Martin B, Wiley J . Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol. 2004; 2(4):305-14. View

10.

Rojas C, Thomas A, Alt J, Stathis M, Zhang J, Rubenstein E . Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2009; 626(2-3):193-9. DOI: 10.1016/j.ejphar.2009.10.002. View

11.

Cohen L, de Moor C, Eisenberg P, Ming E, Hu H . Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2006; 15(5):497-503. DOI: 10.1007/s00520-006-0173-z. View

12.

Roila F, Boschetti E, Tonato M, Basurto C, Bracarda S, Picciafuoco M . Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. A randomized single-blind study. Am J Clin Oncol. 1991; 14(3):238-42. DOI: 10.1097/00000421-199106000-00010. View

13.

Depre M, Van Hecken A, Oeyen M, De Lepeleire I, Laethem T, Rothenberg P . Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol. 2005; 61(5-6):341-6. DOI: 10.1007/s00228-005-0907-8. View

14.

Ho C, Ho S, Wang J, Tsai S, Chai C . Dexamethasone has a central antiemetic mechanism in decerebrated cats. Anesth Analg. 2004; 99(3):734-739. DOI: 10.1213/01.ANE.0000130003.68288.C7. View

15.

Malik I, Khan W, Qazilbash M, Ata E, Butt A, Khan M . Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol. 1995; 18(2):170-5. DOI: 10.1097/00000421-199504000-00017. View

16.

Kris M, Gralla R, Clark R, Tyson L, Fiore J, Kelsen D . Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep. 1985; 69(11):1257-62. View

17.

Miner W, Sanger G, Turner D . Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis. Br J Cancer. 1987; 56(2):159-62. PMC: 2002136. DOI: 10.1038/bjc.1987.177. View

18.

Einhorn L, Brames M, Dreicer R, Nichols C, Cullen Jr M, Bubalo J . Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer. 2007; 15(11):1293-1300. DOI: 10.1007/s00520-007-0255-6. View

19.

Bymaster F, Calligaro D, Falcone J, Marsh R, Moore N, Tye N . Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996; 14(2):87-96. DOI: 10.1016/0893-133X(94)00129-N. View

20.

Fukui H, Yamamoto M, Sato S . Vagal afferent fibers and peripheral 5-HT3 receptors mediate cisplatin-induced emesis in dogs. Jpn J Pharmacol. 1992; 59(2):221-6. DOI: 10.1254/jjp.59.221. View